Anti-factor H antibody associated hemolytic uremic syndrome following SARS-CoV-2 infection.
Alternative complement pathway
Complement factor H related protein
Coronavirus 19
Factor H
Thrombotic microangiopathy
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
07
09
2021
accepted:
15
11
2021
revised:
20
10
2021
pubmed:
29
1
2022
medline:
27
7
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
The pathogenesis of autoantibody generation in anti-factor H (FH) antibody associated atypical hemolytic uremic syndrome (aHUS) is unknown and is perhaps triggered by an infectious or environmental agent. We observed an unusual increase of patients with anti-FH antibody associated aHUS coinciding with the second pandemic wave in New Delhi and suspected that SARS-CoV-2 infection might be a potential trigger. We screened for SARS-CoV-2 infection using reverse transcriptase polymerase chain reaction (RT-PCR) and serology in 13 consecutive patients with anti-FH antibody associated aHUS during the past year in New Delhi. We report 5 patients, 4-13 years old, who presented with a febrile illness without respiratory symptoms during the second pandemic wave. Of these, 3 patients presented with a relapse 25-85 months following the initial episode of aHUS. SARS-CoV-2 was detected by RT-PCR in 1 patient and by serology in 4 patients (median titer 47.1 cut-off index). Patients had high titers of anti-FH antibodies (median 2,300 AU/ml). Genetic studies, done in 3 of the 5 patients, showed homozygous CFHR1 deletion without other significant genetic abnormalities. Specific management comprised plasma exchanges and oral prednisolone, combined with either cyclophosphamide or mycophenolate mofetil. At median follow-up of 3.3 months, the estimated glomerular filtration rate in 4 patients ranged from 62 to 110 ml/min/1.73 m Increased vigilance is required during the pandemic, especially in patients with anti-FH associated aHUS, who might relapse despite quiescent disease for a prolonged period. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
The pathogenesis of autoantibody generation in anti-factor H (FH) antibody associated atypical hemolytic uremic syndrome (aHUS) is unknown and is perhaps triggered by an infectious or environmental agent. We observed an unusual increase of patients with anti-FH antibody associated aHUS coinciding with the second pandemic wave in New Delhi and suspected that SARS-CoV-2 infection might be a potential trigger.
METHODS
We screened for SARS-CoV-2 infection using reverse transcriptase polymerase chain reaction (RT-PCR) and serology in 13 consecutive patients with anti-FH antibody associated aHUS during the past year in New Delhi.
RESULTS
We report 5 patients, 4-13 years old, who presented with a febrile illness without respiratory symptoms during the second pandemic wave. Of these, 3 patients presented with a relapse 25-85 months following the initial episode of aHUS. SARS-CoV-2 was detected by RT-PCR in 1 patient and by serology in 4 patients (median titer 47.1 cut-off index). Patients had high titers of anti-FH antibodies (median 2,300 AU/ml). Genetic studies, done in 3 of the 5 patients, showed homozygous CFHR1 deletion without other significant genetic abnormalities. Specific management comprised plasma exchanges and oral prednisolone, combined with either cyclophosphamide or mycophenolate mofetil. At median follow-up of 3.3 months, the estimated glomerular filtration rate in 4 patients ranged from 62 to 110 ml/min/1.73 m
CONCLUSION
Increased vigilance is required during the pandemic, especially in patients with anti-FH associated aHUS, who might relapse despite quiescent disease for a prolonged period. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 35089377
doi: 10.1007/s00467-021-05390-4
pii: 10.1007/s00467-021-05390-4
pmc: PMC8796738
doi:
Substances chimiques
Autoantibodies
0
Complement Factor H
80295-65-4
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2151-2156Informations de copyright
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390:681–696
doi: 10.1016/S0140-6736(17)30062-4
Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommele A, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Fremeaux-Bacchi V, Global aHUS Registry, (2018) Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94:408–418
doi: 10.1016/j.kint.2018.02.029
Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A, Indian HUS Registry (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151–1160
doi: 10.1038/ki.2013.373
Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A (2019) Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a Nationwide Database. Front Immunol 10:1282
doi: 10.3389/fimmu.2019.01282
Togarsimalemath SK, Si-Mohammed A, Puraswani M, Gupta A, Vabret A, Liguori S, Mariani-Kurkdjian P, Bagga A, Dragon-Durey MA (2018) Gastrointestinal pathogens in anti-FH antibody positive and negative hemolytic uremic syndrome. Pediatr Res 84:118–124
doi: 10.1038/s41390-018-0009-9
Kaufeld J, Reinhardt M, Schroder C, Brasen JH, Wiech T, Brylka P, Khaled A, Bergmann C, Haller H, Gackler A, Schmidt BMW (2021) Atypical HUS triggered by infection with SARS-CoV2. Kidney Int Rep 6:2709–2712
doi: 10.1016/j.ekir.2021.07.004
Mat O, Ghisdal L, Massart A, Aydin S, Goubella A, Blankoff N, Gankam F, Debelle F, Mat Q (2021) Kidney thrombotic microangiopathy after COVID-19 associated with C3 gene mutation. Kidney Int Rep 6:1732–1737
doi: 10.1016/j.ekir.2021.03.897
Ville S, Le Bot S, Chapelet-Debout A, Blancho G, Fremeaux-Bacchi V, Deltombe C, Fakhouri F (2021) Atypical HUS relapse triggered by COVID-19. Kidney Int 99:267–268
doi: 10.1016/j.kint.2020.10.030
Tiwari NR, Phatak S, Sharma VR, Agarwal SK (2021) COVID-19 and thrombotic microangiopathies. Thromb Res 202:191–198
doi: 10.1016/j.thromres.2021.04.012
Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE, Chase J, Liebling EJ, Burudpakdee C, Lee JH, Balamuth FB, Blatz AM, Chiotos K, Fitzgerald JC, Giglia TM, Gollomp K, Odom John AR, Jasen C, Leng T, Petrosa W, Vella LA, Witmer C, Sullivan KE, Laskin BL, Hensley SE, Bassiri H, Behrens EM, Teachey DT (2020) Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv 4:6051–6063
doi: 10.1182/bloodadvances.2020003471
Carvelli J, Demaria O, Vely F, Batista L, Chouaki Benmansour N, Fares J, Carpentier S, Thibult ML, Morel A, Remark R, Andre P, Represa A, Piperoglou C; Explore COVID-19 IPH group; Explore COVID-19 Marseille Immunopole group; Cordier PY, Le Dault E, Guervilly C, Simeone P, Gainnier M, Morel Y, Ebbo M, Schleinitz N, Vivier E (2020) Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature 588:146-150
Ma L, Sahu SK, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang CH, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo AM, Goss CW, O'Halloran JA, Presti RM, Kim AH, Gelman AE, Cruz CD, Lee AI, Mudd P, Chun HJ, Atkinson JP, Kulkarni HS (2021) Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. bioRxiv Preprint. https://doi.org/10.1101/2021.02.22.432177
Yu J, Gerber GF, Chen H, Yuan X, Chaturvedi S, Braunstein EM, Brodsky RA (2021) Complement dysregulation is associated with severe COVID-19 illness. Haematologica. https://doi.org/10.3324/haematol.2021.279155
doi: 10.3324/haematol.2021.279155
pubmed: 34818872
pmcid: 8968890
Galeotti C, Bayry J (2020) Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 16:413–414
doi: 10.1038/s41584-020-0448-7
El-Sissy C, Saldman A, Zanetta G, Vieira-Martins P, Poulain C, Cauchois R, Kaplanski G, Venetz JP, Bobot M, Dobosziewicz H, Daniel L, Koubi M, Sadallah S, Rotman S, Mousson C, Pascual M, Fremeaux-Bacchi V, Fakhouri F (2021) COVID-19 as a potential trigger of complement-mediated atypical HUS. Blood. https://doi.org/10.1182/blood.2021012752
doi: 10.1182/blood.2021012752
pubmed: 34482396
pmcid: 8421074
Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA, Indian Society of Pediatric Nephrology (2019) Hemolytic uremic syndrome in a developing country: consensus guidelines. Pediatr Nephrol 34:1465–1482
doi: 10.1007/s00467-019-04233-7
Khandelwal P, Faruq M, Puraswani M, Sinha A, Bagga A (2018) Coexisting variations in complement regulatory genes increase risk of relapse in anti-Factor H antibody associated atypical hemolytic uremic syndrome. American Society of Nephrology Kidney Week - Abstract Details. https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3024369 . Accessed 8 October 2021
Lopes da Silva R (2011) Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther 4:51–59
doi: 10.5144/1658-3876.2011.51
Mahajan R, Lipton M, Broglie L, Jain NG, Uy NS (2020) Eculizumab treatment for renal failure in a pediatric patient with COVID-19. J Nephrol 33:1373–1376
doi: 10.1007/s40620-020-00858-2
Alizadeh F, O’Halloran A, Alghamdi A, Chen C, Trissal M, Traum A, DeCourcey D (2021) Toddler with new onset diabetes and atypical hemolytic-uremic syndrome in the setting of COVID-19. Pediatrics 147:e2020016774
doi: 10.1542/peds.2020-016774
Durey MA, Sinha A, Togarsimalemath SK, Bagga A (2016) Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 12:563–578
doi: 10.1038/nrneph.2016.99
Bhattacharjee A, Reuter S, Trojnar E, Kolodziejczyk R, Seeberger H, Hyvarinen S, Uzonyi B, Szilagyi A, Prohaszka Z, Goldman A, Jozsi M, Jokiranta TS (2015) The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 290:9500–9510
doi: 10.1074/jbc.M114.630871
Meri T, Amdahl H, Lehtinen MJ, Hyvarinen S, McDowell JV, Bhattacharjee A, Meri S, Marconi R, Goldman A, Jokiranta TS (2013) Microbes bind complement inhibitor factor H via a common site. PLoS Pathog 9:e1003308
doi: 10.1371/journal.ppat.1003308
Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA (2020) Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 136:2080–2089
doi: 10.1182/blood.2020008248
Krishnasamy S, Mantan M, Mishra K, Kapoor K, Brijwal M, Kumar M, Sharma S, Swarnim S, Gaind R, Khandelwal P, Hari P, Sinha A, Bagga A (2021) SARS-CoV-2 infection in children with chronic kidney disease. Pediatr Nephrol. https://doi.org/10.1007/s00467-021-05218-1
doi: 10.1007/s00467-021-05218-1
pubmed: 34519896
pmcid: 8438908
Sharma N, Sharma P, Basu S, Saxena S, Chawla R, Dushyant K, Mundeja N, Marak Z, Singh S, Singh G, Rustagi R (2021) The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study. Trans R Soc Trop Med Hyg. https://doi.org/10.1093/trstmh/trab109
doi: 10.1093/trstmh/trab109
pubmed: 34037804
pmcid: 7928650
Misra P, Kant S, Guleria R, Rai SK; WHO Unity Seroprevalence study team of AIIMS (2021) Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2–17 years) group in India: an interim result from a large multi-centric population-based seroepidemiological study. medRxiv Preprint. https://doi.org/10.1101/2021.06.15.21258880